Metrovacesa Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Metrovacesa wird ein jährliches Gewinn- und Umsatzwachstum von 2.1% bzw. 2.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 1.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 6.2% betragen.
Wichtige Informationen
2.1%
Wachstumsrate der Gewinne
1.71%
EPS-Wachstumsrate
| Real Estate Gewinnwachstum | -0.9% |
| Wachstumsrate der Einnahmen | 2.4% |
| Zukünftige Eigenkapitalrendite | 6.15% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 29 Apr 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • May 02
MVC: Slightly Higher Required Return And Rich P/E Will Constrain Future Upside
Analysts have kept their average price target for Metrovacesa broadly steady around €10.81, citing only slight shifts in discount rate, profit margin assumptions and future P/E expectations rather than any major change in the investment case. Valuation Changes Fair Value: The €10.81 fair value estimate is unchanged, indicating a stable central valuation point in the model.Narrativ-Update • Apr 17
MVC: Higher Required Return And Rich P/E Will Pressure Future Returns
Analysts have kept their price target for Metrovacesa broadly unchanged at around €10.81 per share. The latest revisions reflect only very small model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.Narrativ-Update • Apr 03
MVC: Stable Assumptions And Discount Rate Tweaks Will Guide Future Returns
Analysts keep their Metrovacesa price target steady at €10.81, indicating largely unchanged assumptions on fair value, growth, margins, and future P/E, with only minor adjustments to discount rates and long-term expectations. Valuation Changes Fair Value: €10.81 per share is unchanged, suggesting the core view of what the stock is worth on a fundamental basis remains the same.Narrativ-Update • Mar 20
MVC: Dividend Outlook And Revised Assumptions Will Shape Future Return Balance
Analysts now set their fair value estimate for Metrovacesa at €10.81 per share, up from €10.63. This reflects updated assumptions around the discount rate, revenue growth, profit margin and future P/E.
Narrativ-Update • Mar 06
MVC: Lower Growth Assumptions And Elevated P/E Will Sustain Bearish View
Analysts have modestly lowered their price target on Metrovacesa to €9.30, citing updated assumptions for revenue growth, profit margins and the future P/E multiple, while keeping their fair value estimate unchanged at €9.30. Valuation Changes Fair Value: The fair value estimate is unchanged at €9.30 per share, indicating no revision to the overall valuation outcome.Narrativ-Update • Feb 20
MVC: Dividend Outlook And Updated Assumptions Will Shape Future Return Balance
Analysts have slightly trimmed their fair value estimate for Metrovacesa from €10.83 to €10.63, citing updated assumptions around discount rates, expected revenue growth, margins and future P/E levels. Valuation Changes Fair Value: Trimmed slightly from €10.83 to €10.63 per share.Narrativ-Update • Feb 06
MVC: Lower Discount Rate And High P/E Will Sustain Bearish View
Analysts have slightly raised their price target on Metrovacesa, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E, which together indicate a modestly higher fair value per share in euro terms. Valuation Changes Fair Value: unchanged at €9.30 per share.Narrativ-Update • Jan 23
MVC: Dividend Reserve Plans And P/E Revisions Will Guide Cautious Outlook
Analysts have maintained their Metrovacesa fair value target at €9.30, citing a combination of updated assumptions that include slightly lower discount rates, higher revenue growth expectations, softer profit margins and a higher future P/E multiple in their latest models. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments).
Narrativ-Update • Jan 08
MVC: Dividend Proposal At Extraordinary Meeting Will Support Bullish Thesis
Analysts have revised their price target on Metrovacesa from €11.80 to €13.10, citing updated assumptions around discount rates, revenue growth, profit margins, and the future P/E multiple. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (calle principe de vergara 187, plaza de rodrigo uria, madrid) (Key Developments) The meeting agenda includes a proposal to discuss the distribution of dividends from freely distributable reserves, which may be relevant if you are focusing on potential cash returns to shareholders (Key Developments) The notice also refers to discussion of other matters at the meeting, indicating that additional shareholder topics could be addressed beyond dividends (Key Developments) Valuation Changes Fair Value Estimate was revised from €11.80 to €13.10, indicating a higher assessed value per share.Narrativ-Update • Dec 24
MVC: Dividend Reserve Plans Will Shape A Cautious Medium-Term Outlook
Analysts have raised their price target on Metrovacesa from €6.50 to €9.30, citing higher expected revenue growth, improved profit margins, and a modestly richer future P/E multiple, despite a slightly higher discount rate. What's in the News Metrovacesa has called a special shareholders meeting for November 25, 2025, at 13:00 CET in Madrid to address key corporate matters.Analyseartikel • Dec 20
Metrovacesa S.A. (BME:MVC) Shares Could Be 23% Below Their Intrinsic Value Estimate
Key Insights Metrovacesa's estimated fair value is €11.52 based on 2 Stage Free Cash Flow to Equity Current share price...Narrativ-Update • Dec 10
MVC: Dividend Decision And Revised Outlook Will Shape Balanced Return Prospects
Analysts have raised their price target on Metrovacesa from €9.81 to €10.83, citing a higher long term fair value despite moderating assumptions for revenue growth, profit margins and future earnings multiples. What's in the News Metrovacesa has scheduled a special and extraordinary shareholders meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments) The main agenda item for the upcoming meeting is the potential distribution of dividends from freely distributable reserves, which could affect shareholder returns policy (Key Developments) Shareholders will also address other unspecified matters at the meeting, leaving scope for additional corporate or capital structure decisions (Key Developments) Valuation Changes Fair Value: raised slightly from €9.81 to €10.83 per share, reflecting a modest uplift in long term valuation.Analyseartikel • Oct 02
Should You Think About Buying Metrovacesa S.A. (BME:MVC) Now?
Metrovacesa S.A. ( BME:MVC ), is not the largest company out there, but it had a relatively subdued couple of weeks in...Analyseartikel • Jul 25
Calculating The Fair Value Of Metrovacesa S.A. (BME:MVC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €12.58 Metrovacesa's €10.15...Analyseartikel • May 04
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Apr 12
Are Investors Undervaluing Metrovacesa S.A. (BME:MVC) By 40%?
Key Insights The projected fair value for Metrovacesa is €16.96 based on 2 Stage Free Cash Flow to Equity Metrovacesa...Analyseartikel • Feb 26
Metrovacesa's (BME:MVC) Performance Is Even Better Than Its Earnings Suggest
Even though Metrovacesa S.A.'s ( BME:MVC ) recent earnings release was robust, the market didn't seem to notice. We...
Neues Narrativ • Feb 19
Will Leverage Undersupplied Spanish Housing Market For Future Opportunities
High presales coverage allows focus on margin maximization, boosting future net margins amid an undersupplied market.Analyseartikel • Feb 07
Is It Time To Consider Buying Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it maintained its current share price...Analyseartikel • Dec 13
An Intrinsic Calculation For Metrovacesa S.A. (BME:MVC) Suggests It's 44% Undervalued
Key Insights Metrovacesa's estimated fair value is €16.39 based on 2 Stage Free Cash Flow to Equity Metrovacesa's €9.13...Analyseartikel • Sep 12
Estimating The Fair Value Of Metrovacesa S.A. (BME:MVC)
Key Insights The projected fair value for Metrovacesa is €9.93 based on 2 Stage Free Cash Flow to Equity Metrovacesa's...Analyseartikel • Aug 01
We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve
The subdued stock price reaction suggests that Metrovacesa S.A.'s ( BME:MVC ) strong earnings didn't offer any...Analyseartikel • Jul 17
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it saw significant share price...Analyseartikel • May 28
A Look At The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €9.31 Current share price...Analyseartikel • May 01
We Think Metrovacesa (BME:MVC) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Mar 27
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it received a lot of attention from a...Analyseartikel • Feb 12
A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)
Key Insights The projected fair value for Metrovacesa is €9.08 based on 2 Stage Free Cash Flow to Equity Current share...Analyseartikel • Nov 05
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Jul 05
These 4 Measures Indicate That Metrovacesa (BME:MVC) Is Using Debt Extensively
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • May 21
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not be the most widely known stock at the moment, it saw significant share...Analyseartikel • Apr 19
Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €7.36 Current share price...Analyseartikel • Dec 02
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Sep 23
Is It Too Late To Consider Buying Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not be the most widely known stock at the moment, it received a lot of...Analyseartikel • May 19
Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)
Does the May share price for Metrovacesa S.A. ( BME:MVC ) reflect what it's really worth? Today, we will estimate the...Analyseartikel • Mar 05
Metrovacesa's (BME:MVC) Strong Earnings Are Of Good Quality
Metrovacesa S.A. ( BME:MVC ) just reported healthy earnings but the stock price didn't move much. We think that...Analyseartikel • Feb 16
Would Metrovacesa (BME:MVC) Be Better Off With Less Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analyseartikel • Oct 05
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Jul 02
Is Metrovacesa S.A. (BME:MVC) Worth €6.7 Based On Its Intrinsic Value?
Today we will run through one way of estimating the intrinsic value of Metrovacesa S.A. ( BME:MVC ) by projecting its...Analyseartikel • May 06
Is Metrovacesa (BME:MVC) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Apr 06
Is Metrovacesa S.A. (BME:MVC) A Strong Dividend Stock?
Is Metrovacesa S.A. ( BME:MVC ) a good dividend stock? How can we tell? Dividend paying companies with growing earnings...Analyseartikel • Mar 15
Metrovacesa (BME:MVC) Share Prices Have Dropped 51% In The Last Three Years
Metrovacesa S.A. ( BME:MVC ) shareholders should be happy to see the share price up 12% in the last month. But that...Analyseartikel • Feb 16
Loss-Making Metrovacesa S.A. (BME:MVC) Set To Breakeven
We feel now is a pretty good time to analyse Metrovacesa S.A.'s ( BME:MVC ) business as it appears the company may be...Analyseartikel • Jan 26
When Should You Buy Metrovacesa S.A. (BME:MVC)?
Metrovacesa S.A. ( BME:MVC ), might not be a large cap stock, but it led the BME gainers with a relatively large price...Analyseartikel • Jan 05
A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)
In this article we are going to estimate the intrinsic value of Metrovacesa S.A. ( BME:MVC ) by taking the expected...Analyseartikel • Dec 14
If You Had Bought Metrovacesa's (BME:MVC) Shares A Year Ago You Would Be Down 24%
Metrovacesa S.A. ( BME:MVC ) shareholders should be happy to see the share price up 11% in the last month. But that...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 757 | 62 | 198 | 125 | 2 |
| 12/31/2027 | 780 | 64 | 198 | 184 | 2 |
| 12/31/2026 | 745 | 66 | 183 | 187 | 2 |
| 12/31/2025 | 708 | 57 | 217 | 217 | N/A |
| 9/30/2025 | 632 | 27 | 124 | 124 | N/A |
| 6/30/2025 | 555 | -3 | 31 | 31 | N/A |
| 3/31/2025 | 604 | 6 | 63 | 63 | N/A |
| 12/31/2024 | 653 | 16 | 95 | 95 | N/A |
| 9/30/2024 | 651 | 17 | 75 | 75 | N/A |
| 6/30/2024 | 649 | 18 | 55 | 55 | N/A |
| 3/31/2024 | 616 | -15 | N/A | N/A | N/A |
| 12/31/2023 | 581 | -21 | 32 | 32 | N/A |
| 9/30/2023 | 535 | -68 | N/A | N/A | N/A |
| 6/30/2023 | 430 | -71 | 92 | 92 | N/A |
| 3/31/2023 | 454 | -38 | N/A | N/A | N/A |
| 12/31/2022 | 516 | -23 | 211 | 211 | N/A |
| 9/30/2022 | 529 | 25 | N/A | N/A | N/A |
| 6/30/2022 | 572 | 33 | 227 | 227 | N/A |
| 3/31/2022 | 575 | 31 | N/A | N/A | N/A |
| 12/31/2021 | 512 | 18 | 139 | 139 | N/A |
| 9/30/2021 | 413 | -71 | N/A | N/A | N/A |
| 6/30/2021 | 231 | -90 | -24 | -24 | N/A |
| 3/31/2021 | 138 | -160 | N/A | N/A | N/A |
| 12/31/2020 | 140 | -164 | -78 | -78 | N/A |
| 9/30/2020 | 164 | -87 | N/A | N/A | N/A |
| 6/30/2020 | 180 | -87 | -46 | -45 | N/A |
| 3/31/2020 | 214 | -6 | N/A | N/A | N/A |
| 12/31/2019 | 161 | -4 | -29 | -28 | N/A |
| 9/30/2019 | 206 | 0 | N/A | -15 | N/A |
| 6/30/2019 | 220 | 5 | N/A | 18 | N/A |
| 3/31/2019 | 211 | -11 | N/A | 21 | N/A |
| 12/31/2018 | 190 | -9 | N/A | 35 | N/A |
| 9/30/2018 | 103 | -14 | N/A | 147 | N/A |
| 6/30/2018 | 70 | -31 | N/A | -19 | N/A |
| 3/31/2018 | 34 | -34 | N/A | -38 | N/A |
| 12/31/2017 | 28 | -39 | N/A | -27 | N/A |
| 9/30/2017 | 29 | -55 | N/A | -172 | N/A |
| 12/31/2016 | 21 | -21 | N/A | 21 | N/A |
| 12/31/2015 | 36 | 64 | N/A | -62 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: MVCDas prognostizierte Gewinnwachstum (2.1% pro Jahr) liegt unter der Sparquote (2.7%).
Ertrag vs. Markt: MVCDie Erträge des Unternehmens (2.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Spanish (11.6% pro Jahr).
Hohe Wachstumserträge: MVCDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: MVCDie Einnahmen des Unternehmens (2.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Spanish (6.4% pro Jahr).
Hohe Wachstumseinnahmen: MVCDie Einnahmen des Unternehmens (2.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: MVCDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (6.2%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/21 18:50 |
| Aktienkurs zum Tagesende | 2026/05/21 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Metrovacesa S.A. wird von 22 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Ignacio Romero | Banco de Sabadell. S.A. |
| null null | Banco de Sabadell. S.A. |
| Mariano Miguel Hidalgo | Banco Santander |